Amneal Pharmaceuticals, Inc. (FRA:2DT)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.28B +30.8% |
| Revenue (ttm) | 2.57B +8.0% |
| Net Income | 61.37M |
| EPS | 0.19 |
| Shares Out | n/a |
| PE Ratio | 53.46 |
| Forward PE | 11.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 139 |
| Open | 10.30 |
| Previous Close | 10.30 |
| Day's Range | 10.20 - 10.30 |
| 52-Week Range | 5.70 - 12.60 |
| Beta | n/a |
| RSI | 39.47 |
| Earnings Date | May 1, 2026 |
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
News
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy
Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421m,...
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amneal to Participate in Upcoming Investor Conference
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside ch...
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per...
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) w...
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full ...
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research...
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership...
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks
Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several...
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approv...
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVA...
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approv...
Amneal to Participate in Upcoming Investor Conferences
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financi...
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Approval underscores Amneal's advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIR...
Amneal Receives U.S. FDA Approval for Iohexol Injection
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved th...
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. ( AMRX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Anthony DiMeo - Head of Investor Relations Chirag Patel - Co-Founder, Co-CEO, President & ...
Amneal Reports Third Quarter 2025 Financial Results
‒ Q3 2025 Net Revenue of $785 million ; GAAP Net Income of $2 million ; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million ; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year...
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved ...
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine m...
Amneal to Report Third Quarter 2025 Results on October 30, 2025
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will...
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver...